AVX754 (a New Nucleoside Reverse Transcriptase Inhibitor [NRTI]) to Treat Drug-resistant HIV

NCT00126880 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: AVX754
DRUG: 3TC

Sponsor

Avexa